Abstract 2537: Recombinant Human Antithrombin III Improves Myocardial Function and Reduces Systemic Vascular Permeability After...
Introduction: With more than 1 billion injuries every year, burns represent a major source of morbidity and mortality in the United States.. Hypothesis: We hypothesized that a continuous intravenous (iv) infusion of recombinant human antithrombin III (rhAT III) reduces the myocardial depression and the vascular permeability associated with combined burn and smoke inhalation injury. Therefore, the present prospective, randomized experiment was conducted using an established ovine model.. Methods: After instrumentation for chronic hemodynamic monitoring and 5 days of recovery, a tracheostomy as well as a 40% total body surface area 3rd° cutaneous burn and smoke inhalation injury (48 breaths of cold cotton smoke ,40°C) were performed in 12 sheep under deep anesthesia. The sheep were then randomized to receive either an iv infusion of 6 IU·kg−1·h−1 rhAT III (started 1 h after injury) or normal saline (n=6 each). All sheep were awake, ...http://circ.ahajournals.org/content/120/Suppl_18/S656.3
Human Antithrombin III ELISA Kit (ab108801) | Abcam
Abcam's Antithrombin III ELISA Kit suitable for Cell culture supernatant, Saliva, Milk, Urine, Serum, Plasma, Cell culture media, Cerebral Spinal Fluid in…http://www.abcam.com/human-antithrombin-iii-elisa-kit-ab108801.html
Recombinant Human Antithrombin - XVIVO | Scientific Animation
ATryn® (also known as ATIII) is a recombinant form of human antithrombin. This product demonstrates the high potential for the use of transgenic technology in the production of biotherapeutics. Antithrombin is a plasma protein with anti-coagulative and anti-inflammatory properties that, like many other proteins currently derived from human blood supply, has been difficult to manufacture using conventional recombinant protein production methods.. ...http://www.xvivo.net/animation/recombinant-human-antithrombin/
eCite - Combined effect of plasma antithrombin III and platelet factor 4 levels in the development of heparin resistance during...
Combined effect of plasma antithrombin III and platelet factor 4 levels in the development of heparin resistance during cardiac bypass surgeryhttp://ecite.utas.edu.au/43936
Antithrombin III and Fibrinogen as Predictors of Cardiac Events in Patients With Angina Pectoris | Arteriosclerosis, Thrombosis...
This study is the first to evaluate the long-term prognostic significance of hemostatic factor measurements in patients with angina pectoris and known coronary angiographic status. The clinical follow-up spanned 9.5 years, and complete follow-up information was available for 93% of the 225 patients initially recruited to the study. Although the number of patients investigated was comparatively small, the 58 patients with cardiac events, who represented more than a quarter of the original patient sample, allowed meaningful conclusions on risk relationships with hemostatic and angiographic baseline variables. Some earlier cross-sectional studies have indicated lower antithrombin III antigen or activity in patients with CAD compared with individuals without,32 33 34 35 while others have reported higher rather than lower values.36 37 In contrast, more recent investigations in large populations or patient cohorts failed to demonstrate an association of ...http://atvb.ahajournals.org/content/16/3/357
Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis - Tabular View -...
The primary objective of the study is to explore the efficacy and safety of ATryn® (antithrombin alfa) for the treatment of disseminated intravascular coagulation (DIC) associated with severe sepsis, when administered by continuous intravenous (IV) infusion over five days ...https://clinicaltrials.gov/ct2/show/record/NCT00506519
antithrombin III Glasgow Summary Report | CureHunter
antithrombin III Glasgow: abnormal antithrombin with increased heparin affinity & reduced ability to inactivate thrombin; associated with familial thrombosis; tryptic peptides Ala(371)-Arg(393) & Ser(394)-Arg(399) present in reduced amounts; Asp(187) replaced by Lyshttp://www.curehunter.com/public/keywordSummaryC054089-antithrombin-III-Glasgow.do
Antithrombin (Activity and Antigen) - Health Encyclopedia - University of Rochester Medical Center
Test results may vary depending on your age, gender, health history, the method used for the test, and other things. Your test results may not mean you have a problem. Ask your healthcare provider what your test results mean for you. The results for both activity and antigen tests are given as percentages. Different labs use slightly different normal ranges, but in general, 80% to 120% is considered normal for adults. Newborns usually have about half as much antithrombin as adults. Thrombin levels in infants rise to adult levels by about 6 months of age. People with genetically inherited antithrombin deficiency typically have test results between 40% and 60%. In both type 1 and type 2 AT deficiency, the antithrombin activity test shows a low result because you don't have as much working antithrombin as you should have. When the AT activity test shows that levels are low, the antithrombin antigen test can then be used to find ...https://www.urmc.rochester.edu/encyclopedia/content.aspx?ContentTypeID=167&ContentID=antithrombin_activity_antigen
Gentaur Molecular :Assaypro \ Antithrombin III, anti human \ 12161-05025
Gentaur molecular products has all kinds of products like :search , Assaypro \ Antithrombin III, anti_human \ 12161-05025 for more molecular products just contact ushttp://www.antibody-antibodies.com/product_det.php?id=1761655&supplier=search&name=Antithrombin%20III,%20anti_human
Gentaur Molecular :Accu \ Antithrombin III, Goat anti Human \ ACL20016A
Gentaur molecular products has all kinds of products like :search , Accu \ Antithrombin III, Goat anti_Human \ ACL20016A for more molecular products just contact ushttp://www.antibody-antibodies.com/product_det.php?id=18615&supplier=search&name=Antithrombin%20III,%20Goat%20anti_Human
antithrombin III ELISA Kits | Biocompare.com
1 reviews. Compare antithrombin III ELISA Kits from leading suppliers on Biocompare. View specifications, prices, citations, reviews, and more.http://www.biocompare.com/pfu/110627/soids/2-338694/Assay_Kit/ELISA_antithrombin_III
Antithrombin III 293T transfected lysate (ab94043)
Buy our Antithrombin III 293T transfected lysate (positive control). ab94043 has been validated in western blot. Abcam now offers a 12-month guarantee.http://www.abcam.com/antithrombin-iii-overexpression-293t-lysate-whole-cell-ab94043.html
Most recent papers with the keyword international normalized ratio AND arthroplasty | Read by QxMD
OBJECTIVE: To evaluate the efficacy and safety of fondaparinux compared with nadroparin for prevention of venous thromboembolism after arthroplasty. PATIENTS AND METHODS: One hundred fifteen patients were randomized into 2 treatment groups. Patients were given fondaparinux in Group I and nadroparin in Group II. Measurements were performed on Days 1, 5, and 21. The wound area was assessed with a subjective visual analog scale. RESULTS: The blood counts, clinical biochemical tests, and coagulation tests (ie, thrombin time, partial thromboplastin time, activated partial thromboplastin time, fibrinogen, prothrombin time-International Normalized Ratio, and antithrombin III activity) did not show statistically significant differences between Group I and Group II ...https://www.readbyqxmd.com/keyword/19960
Serpin C1/Antithrombin-III Antibodies: Novus Biologicals
Serpin C1/Antithrombin-III Antibodies available through Novus Biologicals. Browse our Serpin C1/Antithrombin-III Antibody catalog backed by our Guarantee+.https://www.novusbio.com/primary-antibodies/serpin-c1-antithrombin-iii
Native Human Serpin C1/Antithrombin-III | Cell Sciences
AT3, ATIII, MGC22579, OTTHUMP00000035393, antithrombin (aa 375-432), antithrombin III, coding sequence signal peptide antithrombin part 1, serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, signal peptide antithrombin part 1 ...http://www.cellsciences.com/native-human-serpin-c1-antithrombin-iii
Anti-thrombin III (ATIII) vs Placebo in Children (|7mo) Undergoing Open Congenital Cardiac Surgery - Full Text View -...
Evidence of decreased activation of the coagulation and fibrinolytic systems represented by a difference in the mean of the ATIII (functional assay) of the control and ATIII groups at T1, T2, T3, T5, T6 and T7 (Baseline, 30 min after study drug, 30 min on CPB, Arrival in ICU, POD 2, and POD 4). Data reported as % Functional Activity, which is calculated as the ability of Antithrombin (AT) to suppress FIIa or FXa in the presence of heparin compared to normograms, and expressed as a percentage ...https://clinicaltrials.gov/ct2/show/NCT02103114?cond=%22antithrombin+deficiency%22&rank=5
Antithrombin Activators Overview, Forecast & Analysis 2016 | Healthcare
Before It's News). Publisher's, "Antithrombin Activators-Pipeline Insights, 2016″, report provides in depth insights on the pipeline drugs and their development activities around the Antithrombin Activators. The Publisher's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publisher's Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Antithrombin Activators. Publisher's Report also assesses the Antithrombin Activators therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.. For more information about this ...http://beforeitsnews.com/healthcare/2016/11/antithrombin-activators-overview-forecast-analysis-2016-2488958.html
Transgenic Rabbits to Prepare Pharmaceutical Proteins | SpringerLink
The preparation of recombinant pharmaceutical proteins is one of the major challenges of biotechnology. Mammalian cells are required for a number of proteins which must be modified posttranscriptionally. Animal cell lines cultured in fermentors are presently the major source of complex proteins. The milk of transgenic animals proved to be a possible source of pharmaceutical proteins and one of them, human antithrombin III, has been approved by the EU (EMEA) and US (FDA) medicament agencies. Several species are being implemented for this purpose. Rabbits are one of these species. It offers several advantages: low cost to produce transgenic founders, rapid reproduction, easy and cheap scaling up, easy breeding in pathogen-free conditions and insensitivity to prion diseases. Rabbits are thus an efficient tool to prepare several kilograms of a recombinant protein per year. ...https://link.springer.com/chapter/10.1007/978-90-481-2227-1_8
Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. |...
METHODS AND RESULTS Fifty-five patients were treated with urokinase-preactivated prourokinase (n = 35) or tissue-type plasminogen activator (n = 20) for acute myocardial infarction and underwent coronary angiography at 90 minutes and at 24-36 hours into thrombolysis, and fibrinogen (Ratnoff-Menzie), D-dimer (ELISA) and thrombin-antithrombin III complex levels (ELISA) were measured. Primary patency was achieved in 39 patients (70.9%), 13 of whom (33.3%) suffered early reocclusion. Nonsignificant decreases in fibrinogen levels were observed while D-dimer levels increased +3,008 +/- 4,047 micrograms/l (p less than 0.01), differences not being significant in respect to the thrombolytic agents or to the clinical course. In contrast, while thrombin-antithrombin III complex levels decreased -4.4 +/- 13.0 micrograms/l in patients with persistent patency, they increased +7.5 +/- 13.6 micrograms/l in case of nonsuccessful thrombolysis (p less than ...http://circ.ahajournals.org/content/83/3/937
Antithrombin III: US, Europe, Japan-Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next ten years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and AT III testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the AT III testing closer to the patient, creating additional opportunities and challenges for suppliers.. This report presents a detailed analysis of the AT III testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- and 10-year test volume forecasts by country and market segment.. The ...https://www.bigmarketresearch.com/antithrombin-iii-us-europe-japan-analysis-competitive-intelligence-technology-trends-opportunities-for-suppliers-market
Medical Advisor Journals, Kyle J. Norton Site, Health Tips for Better Living and Living Health: The Effects of Hormone...
Antithrombin III (AT III) supplementation has proven to be effective in the treatment of disseminated intravascular coagulation. According to the study by the Kumamoto University School of Medicine , administration of AT III is also useful for prevention of organ failure in animals challenged with endotoxin or bacteria and it increases the survival rate of such animals. Since inhibition of coagulation abnormalities failed to prevent organ failure in animals given bacteria, AT III may exert a therapeutic effect independent of its anticoagulant effect. This therapeutic mechanism of AT III has been explored using an animal model of septicemia. AT III prevented pulmonary vascular injury by inhibiting leukocyte activation in rats given endotoxin. This effect is mediated by the promotion of endothelial release of prostacyclin which inhibits leukocyte activation. Interaction of AT ...https://kylejnorton.blogspot.ca/2013/12/the-effects-of-hormone-prostacyclin3.html
Fondaparinux - Wikipedia
Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically related to low molecular weight heparins. It is marketed by GlaxoSmithKline. A generic version developed by Alchemia is marketed within the US by Dr. Reddy's Laboratories. Fondaparinux is a synthetic pentasaccharide factor Xa inhibitor. Apart from the O-methyl group at the reducing end of the molecule, the identity and sequence of the five monomeric sugar units contained in fondaparinux is identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparin sulfate (HS). Within heparin and heparin sulfate this monomeric sequence is thought to form the high-affinity binding site for the anti-coagulant factor antithrombin III (ATIII). Binding of heparin/HS to ATIII has been shown to increase the anti-coagulant activity of antithrombin ...https://en.wikipedia.org/wiki/Fondaparinux
Abdominal Surgeries - DrugBank
Fondaparinux (Arixtra) is a synthetic pentasaccharide anticoagulant. Apart from the O-methyl group at the reducing end of the molecule, the identity and sequence of the five monomeric sugar units contained in fondaparinux is identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycan heparin and heparan sulfate (HS). This monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Binding of heparin/HS to ATIII has been shown to increase the anti-coagulant activity of antithrombin III 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower ...https://www.drugbank.ca/indications/DBCOND0038347
Preferred Name: Tinzaparin Sodium Definition: The sodium salt of a low molecular weight heparin (LMWH), obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa, with antithrombotic properties. Tinzaparin is a potent inhibitor of several activated coagulation factors, especially Factors Xa and IIa (thrombin); its primary activity is mediated through the plasma protease inhibitor antithrombin. In addition, this agent may inhibit angiogenesis through: 1) competitive binding of the heparin-binding sites on endothelial cells for the proangiogenic cytokines vascular endothelial growth factor (VEGF) and beta-fibroblast growth factor (beta-FGF) and 2) increasing the release of tissue factor pathway inhibitor (TFPI), a negative regulator of angiogenesis. NCI-GLOSS Definition: A drug that is used with another drug, warfarin, to treat blood clots that form deep in the veins and to prevent new blood clots from forming. It is a type of anticoagulant. Display Name: ...https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C60810
Antithrombin elisa and antibody
Shop Antithrombin ELISA Kit, Recombinant Protein and Antithrombin Antibody at MyBioSource. Custom ELISA Kit, Recombinant Protein and Antibody are available.https://www.mybiosource.com/protein_family.php?root=antithrombin